Unicycive TherapeuticsUNCY
13F holders, Q2 2025 (June 30)20holders
1famous investor
$4.79avg. 13F price*
At the end of Q2 2025, 20 institutions reported holding Unicycive Therapeutics Inc. (UNCY) in their 13F filings. The largest holders were Vivo Capital, LLC ($5.4M), Octagon Capital Advisors LP ($4.8M) and Nantahala Capital Management, LLC ($4.6M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Unicycive Therapeutics Inc.
- CUSIP
- 90466Y202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $112K |
| Exits | 0 | $0 |
Ownership 20 holders
| Vivo Capital, LLC | 0.56% | No change | 1,137,015 | $5.4M |
| Octagon Capital Advisors LP | 1.05% | No change | 1,000,000 | $4.8M |
| Nantahala Capital Management, LLC | 0.32% | No change | 939,202 | $4.6M |
| Great Point Partners LLC | 2.47% | Reduce -27.4% | 796,558 | $3.8M |
| Vanguard Group Inc. | 0.00% | Add +399.8% | 605,953 | $2.9M |
| Logos Global Management LP | 0.30% | Reduce -6.8% | 473,562 | $2.3M |
| Acuta Capital Partners, LLC | 0.42% | Reduce -73.3% | 62,899 | $300K |
| Geode Capital Management, LLC | 0.00% | Add +1.5% | 58,786 | $280K |
| JPMorgan Chase & Co. | 0.00% | Add +117883.7% | 21,709 | $104K |
| State Street Corp. | 0.00% | No change | 12,523 | $60K |
| Renaissance Technologies | 0.00% | New | 11,790 | $56K |
| Lazard Asset Management LLC | 0.00% | New | 11,575 | $55K |
| Northern Trust Corp. | 0.00% | No change | 10,787 | $51K |
| Morgan Stanley | 0.00% | Reduce -55.1% | 1,000 | $5K |
| SBI Securities Co., Ltd. | 0.00% | Add +22020.0% | 553 | $3K |
| Harbour Investments, Inc. | 0.00% | New | 100 | $477 |
| Barclays PLC | 0.00% | New | 80 | $382 |
| Bank of America Corp. | 0.00% | Add +49.5% | 64 | $305 |
| Bogart Wealth, LLC | 0.00% | No change | 6 | $29 |
| Danske Bank A/S | 0.00% | New | 1 | $5 |
"% of holder's portfolio" is UNCY's weight in each manager's 13F, not the share of Unicycive Therapeutics Inc. the manager owns.